20 rue Jean Mazen
34 articles with Oncodesign SA
Servier to be granted option to exclusively license one or several drug candidates as soon as they are approved to enter phase 1
Oncodesign (Paris:ALONC) (ALONC – FR0011766229), a biopharmaceutical group specialized in precision medicine, is announcing a service partnership with Galderma, a dermatological unit belonging to Nestlé Skin Health.
Oncodesign: Promising Clinical Results for Innovative Mutated anti-EGFR Radiotracer in Patients With Non-Small Cell Lung Cancer
The first stage of the clinical trial, in 8 patients with EGFR mutations, has produced very encouraging results in terms of product safety, dosage and fixing on pulmonary tumors expressing mutated EGFR.
Oncodesign Announces Positive Results Opening the Way for The ALK1 Program to Advance to the Lead Optimization Phase
The company has obtained positive results opening the way for the ALK1 kinase inhibitor discovery program to move on to the lead optimization phase.
Oncodesign, a biopharmaceutical group specialized in precision medicine, and UNICANCER present the details of the OncoSNIPE project, which aims to develop and apply artificial intelligence techniques to cancer research.
Oncodesign SA Presents Its Latest Scientific Developments At The AACR Annual Global Meeting On Oncology
Oncodesign SA Completes The Acquisition Of François Hyafil Research Centre And Appoints Two New Strategic Activity Directors
GlaxoSmithKline And Oncodesign SA Announce Agreement For Oncodesign’s Acquisition Of GSK’s Research Centre In France
Oncodesign SA Announces The Launch Of Its First Clinical Study On A Radiotracer In Patients With Non-Small Cell Lung Cancer
Oncodesign SA And Ipsen Enter Into A Strategic Partnership In Oncology And Oncodesign Joins Ipsen’s Paris-Saclay Campus
Oncodesign SA Presents Novel LRRK2 Inhibitor Jointly Discovered With Ipsen At The 2015 Neurosciences Meeting In Chicago
Oncodesign SA Has Entered Into A Services Agreement With Eisai Inc. To Develop A New Personalized Medicine Program In Earlier Line Metastatic Breast Cancer Treatment
Oncodesign SA And UCB, Inc. Enter Into A Research Collaboration For The Early Development Of New Therapeutic Agents In Neurodegenerative Diseases
Oncodesign SA and Banook Central Imaging Sign a Collaboration Agreement to Develop Biomarkers in Clinical Imaging
Oncodesign SA Signs a Partnership Agreement and an Option for Exclusive Licensing With Sanofi (France) in the Area of Tissue Protection and Repair